Seamus Fernandez
Stock Analyst at Guggenheim
(4.71)
# 149
Out of 5,156 analysts
121
Total ratings
62.5%
Success rate
29.66%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $34 → $35 | $24.82 | +41.02% | 4 | Feb 27, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $140 → $143 | $93.00 | +53.76% | 4 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $72 | $60.63 | +18.75% | 14 | Feb 6, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $27 | $5.38 | +401.86% | 1 | Feb 3, 2026 | |
| PCVX Vaxcyte | Reiterates: Buy | $116 | $59.32 | +95.55% | 5 | Feb 2, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,163 → $1,161 | $1,008.39 | +15.13% | 23 | Jan 20, 2026 | |
| GPCR Structure Therapeutics | Maintains: Buy | $90 → $140 | $56.50 | +147.79% | 3 | Jan 20, 2026 | |
| MBX MBX Biosciences | Maintains: Buy | $77 → $88 | $27.94 | +214.96% | 5 | Jan 16, 2026 | |
| TENX Tenax Therapeutics | Maintains: Buy | $14 → $25 | $11.02 | +126.86% | 3 | Dec 17, 2025 | |
| SNY Sanofi | Downgrades: Neutral | n/a | $44.35 | - | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $6.38 | +72.41% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.36 | - | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $25 | $14.31 | +74.70% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $116 | $74.94 | +54.79% | 8 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $27.24 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $117.11 | +4.18% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $55.51 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.88 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $39.78 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $162.79 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.02 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $3.39 | +1,492.92% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $30.73 | +46.44% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $194.95 | -80.51% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $26.81 | +41.74% | 3 | Jan 31, 2018 |
Arcutis Biotherapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $24.82
Upside: +41.02%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Buy
Price Target: $140 → $143
Current: $93.00
Upside: +53.76%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Buy
Price Target: $62 → $72
Current: $60.63
Upside: +18.75%
Sagimet Biosciences
Feb 3, 2026
Initiates: Buy
Price Target: $27
Current: $5.38
Upside: +401.86%
Vaxcyte
Feb 2, 2026
Reiterates: Buy
Price Target: $116
Current: $59.32
Upside: +95.55%
Eli Lilly and Company
Jan 20, 2026
Maintains: Buy
Price Target: $1,163 → $1,161
Current: $1,008.39
Upside: +15.13%
Structure Therapeutics
Jan 20, 2026
Maintains: Buy
Price Target: $90 → $140
Current: $56.50
Upside: +147.79%
MBX Biosciences
Jan 16, 2026
Maintains: Buy
Price Target: $77 → $88
Current: $27.94
Upside: +214.96%
Tenax Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $14 → $25
Current: $11.02
Upside: +126.86%
Sanofi
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $44.35
Upside: -
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $6.38
Upside: +72.41%
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $7.36
Upside: -
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $14.31
Upside: +74.70%
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $74.94
Upside: +54.79%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $27.24
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $117.11
Upside: +4.18%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $55.51
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.88
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $39.78
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $162.79
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.02
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $3.39
Upside: +1,492.92%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $30.73
Upside: +46.44%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $194.95
Upside: -80.51%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $26.81
Upside: +41.74%